Karen A Gelmon

The cost and cost trajectory of whole‐genome analysis guiding treatment of patients with advanced cancers

Stephen Yip, Deirdre Weymann, Janessa Laskin, 2017, Molecular genetics & genomic medicine.

Preferential dependence of breast cancer cells versus normal cells on integrin-linked kinase for protein kinase B/Akt activation and cell survival.

Karen A Gelmon, Elizabeth D. Wederell, E. Wederell, 2006, Cancer research.

P-cadherin expression as a prognostic biomarker in a 3992 case tissue microarray series of breast cancer

Karen A Gelmon, Paul A Rejto, David G Huntsman, 2011, Modern Pathology.

Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163.

Eric Sauerbrei, Stephen Chia, Karen A Gelmon, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Population-based validation of the prognostic model ADJUVANT! for early breast cancer.

Karen A Gelmon, K. Gelmon, P. Ravdin, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Immunohistochemical detection using the new rabbit monoclonal antibody SP1 of estrogen receptor in breast cancer is superior to mouse monoclonal antibody 1D5 in predicting survival.

Karen A Gelmon, David Huntsman, C Blake Gilks, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27--a randomized controlled phase III trial.

Karen A Gelmon, James N Ingle, Vered Stearns, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Exemestane for breast-cancer prevention in postmenopausal women.

Karen A Gelmon, Dongsheng Tu, James N Ingle, 2011, The New England journal of medicine.